Next-generation sequencing (NGS)

下一代测序 ( NGS )
  • 文章类型: Journal Article
    胰腺癌,随着发病率的惊人上升,预计到2040年将成为第二致命的实体瘤,这凸显了对改进诊断和治疗策略的迫切需要。尽管医学上取得了进步,胰腺癌的5年生存率保持在14%左右,转移时进一步下降。这篇综述探讨了早期检测生物标志物的前景,个性化治疗,和疾病监测。基于基因突变的胰腺癌分子分型,基因表达,蛋白质标记指导治疗决策,有可能改善结果。目前正在进行大量研究不同策略的临床试验。靶向治疗,其中反对CLAUDIN18.2和抑制Claudin18.1的人表现出了希望。下一代测序(NGS)已成为胰腺肿瘤全面基因组分析的强大工具,揭示了驱动癌症进展的独特遗传改变。这使肿瘤学家能够针对特定的分子异常定制治疗方法。然而,挑战依然存在,包括对生物标志物指导疗法的认识和吸收有限。继续研究胰腺癌的分子机制对于开发更有效的治疗方法和提高患者生存率至关重要。
    Pancreatic cancer, with its alarming rising incidence, is predicted to become the second deadliest type of solid tumor by 2040, highlighting the urgent need for improved diagnostic and treatment strategies. Despite medical advancements, the five-year survival rate for pancreatic cancer remains about 14%, dropping further when metastasized. This review explores the promise of biomarkers for early detection, personalized treatment, and disease monitoring. Molecular classification of pancreatic cancer into subtypes based on genetic mutations, gene expression, and protein markers guides treatment decisions, potentially improving outcomes. A plethora of clinical trials investigating different strategies are currently ongoing. Targeted therapies, among which those against CLAUDIN 18.2 and inhibitors of Claudin 18.1, have shown promise. Next-generation sequencing (NGS) has emerged as a powerful tool for the comprehensive genomic analysis of pancreatic tumors, revealing unique genetic alterations that drive cancer progression. This allows oncologists to tailor therapies to target specific molecular abnormalities. However, challenges remain, including limited awareness and uptake of biomarker-guided therapies. Continued research into the molecular mechanisms of pancreatic cancer is essential for developing more effective treatments and improving patient survival rates.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    尽管下一代测序(NGS)在晚期肺腺癌中的广泛应用,它对生存的影响和检查的最佳时机仍然不确定。这项队列研究包括接受NGS检测的晚期肺腺癌患者。我们将患者分为四组:第1组:未治疗,前期NGS;第2组:幼稚治疗,排除性EGFR/ALK/ROS1;第3组:治疗后,无已知EGFR/ALK/ROS1;第4组:已知驱动突变和TKI后治疗。共纳入424例患者。在第1、2、3和4组中分别有128、126、90和80名患者。在第1、2、3和4组中,76.6%的人发现了可靶向突变,49.2%,41.1%,33.3%的病人,分别(p<0.001)。68.0%采用突变靶向治疗,15.1%,27.8%,22.5%的病人,分别(p<0.001)。在总人口中,接受突变靶向治疗的患者表现出显著更长的总生存期(OS)(aHR0.54[95%CI0.37-0.79],p=0.001)。在第1组患者中看到了最深远的益处(未达到vs.40.4个月,p=0.028)。在第2组患者中,采用突变靶向治疗的患者的中位OS也明显更长。在第3组和第4组患者中,接受靶向突变治疗的患者的NGS后生存期中位数在数值上更长。总之,突变靶向治疗与良好的预后相关.然而,NGS导向治疗的机会和突变靶向治疗的生存获益在不同人群中不同.
    Despite the widespread application of next-generation sequencing (NGS) in advanced lung adenocarcinoma, its impact on survival and the optimal timing for the examination remain uncertain. This cohort study included advanced lung adenocarcinoma patients who underwent NGS testing. We categorized patients into four groups: Group 1: treatment-naïve, upfront NGS; Group 2: Treatment-naïve, exclusionary EGFR/ALK/ROS1; Group 3: post-treatment, no known EGFR/ALK/ROS1; Group 4: known driver mutation and post-TKI treatment. A total of 424 patients were included. There were 128, 126, 90, and 80 patients in Groups 1, 2, 3, and 4, respectively. In Groups 1, 2, 3, and 4, targetable mutations were identified in 76.6%, 49.2%, 41.1%, and 33.3% of the patients, respectively (p < 0.001). Mutation-targeted treatments were applied in 68.0%, 15.1%, 27.8%, and 22.5% of the patients, respectively (p < 0.001). In the overall population, patients receiving mutation-targeted treatments exhibited significantly longer overall survival (OS) (aHR 0.54 [95% CI 0.37-0.79], p = 0.001). The most profound benefit was seen in the Group 1 patients (not reached vs. 40.4 months, p = 0.028). The median OS of patients with mutation-targeted treatments was also significantly longer among Group 2 patients. The median post-NGS survival of patients receiving mutation-targeted treatments was numerically longer in Group 3 and Group 4 patients. In conclusion, mutation-targeted therapy is associated with a favorable outcome. However, the opportunities of NGS-directed treatment and the survival benefits of mutation-targeted treatment were various among different populations.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    驱动基因是靶向治疗功效的重要预测因子。检测肺腺癌(LUAD)患者的驱动基因突变可以帮助筛选靶向药物并提高患者的生存效益。本研究旨在探讨LUAD中驱动基因的突变特征及其与临床病理特征的相关性。
    在2019年7月至2022年9月期间,共从邵逸夫爵士医院选择了440名LUAD患者。使用下一代测序技术分析术后组织标本的基因突变,聚焦,包括表皮生长因子受体EGFR,ALK,ROS1,RET,KRAS,MET,BRAF,HER2、PIK3CA和NRAS。同时,收集并整理临床病理资料进行多维相关分析.
    440名LUAD患者,48例患者未检测到驱动基因突变.驱动基因突变的患者比例高达89.09%。前三个驱动基因突变是EGFR,KRAS,和MET。共检测到69种类型的EGFR突变,并分布在蛋白酪氨酸激酶催化域(56,81.16%),富弗林蛋白酶样半胱氨酸区(9,13.04%),受体结合域(3,4.35%),和EGFR跨膜结构域(1,1.45%)。343例LUAD患者发生单基因位点突变,但是突变基因类型涵盖了所有测试基因。我们的研究结果表明,EGFR突变更常见于非吸烟和女性患者(P<0.01)。KRAS突变在男性患者和吸烟者中更为普遍(P<0.01)。ROS1突变的肿瘤直径较大(P<0.01),RET突变在吸烟者中更为普遍(P<0.05)。
    LUAD患者表现出不同的基因突变,这可能同时发生。多种突变的综合分析对于疾病的准确诊断和有效治疗至关重要。使用NGS可以大大扩展我们对基因突变的理解,并促进对多个基因突变的综合分析,为有针对性的治疗方法提供关键证据。
    UNASSIGNED: Driver genes are essential predictors of targeted therapeutic efficacy. Detecting driver gene mutations in lung adenocarcinoma (LUAD) patients can help to screen for targeted drugs and improve patient survival benefits. This study aims to investigate the mutation characterization of driver genes and their correlation with clinicopathological features in LUAD.
    UNASSIGNED: A total of 440 LUAD patients were selected from Sir Run Run Shaw Hospital between July 2019 and September 2022. Postoperative tissue specimens were analyzed for gene mutations using next-generation sequencing technology, focusing, including epidermal growth factor receptor EGFR, ALK, ROS1, RET, KRAS, MET, BRAF, HER2, PIK3CA and NRAS. At the same time, clinicopathological data were collected and organized for multidimensional correlation analysis.
    UNASSIGNED: Of 440 LUAD patients, driver gene mutations were not detected in 48 patients. The proportion of patients with driver gene mutations was as high as 89.09%. The top three driver genetic mutations were EGFR, KRAS, and MET. Sixty-nine types of EGFR mutations were detected and distributed in the protein tyrosine kinase catalytic domain (56, 81.16%), Furin-like cysteine-rich region (9, 13.04%), receptor binding domain (3, 4.35%), and EGFR transmembrane domain (1, 1.45%). Single gene locus mutation occurred in 343 LUAD patients, but the mutation gene types covered all tested genes. Our findings showed that EGFR mutations were more commonly observed in non-smoking and female patients (P<0.01), KRAS mutations were more prevalent in male patients and smokers (P<0.01), ROS1 mutations had larger tumor diameters (P<0.01) and RET mutations were more prevalent in smokers (P<0.05).
    UNASSIGNED: LUAD patients exhibit diverse genetic mutations, which may co-occur simultaneously. Integrated analysis of multiple mutations is essential for accurate diagnosis and effective treatment of the disease. The use of NGS can significantly expand our understanding of gene mutations and facilitate integrated analysis of multiple gene mutations, providing critical evidence for targeted treatment methods.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    Epilithic生物膜在大型河流环境中无处不在,对生物地球化学过程至关重要,但是他们的社区结构和功能仍然知之甚少。在本文中,使用电子显微镜跟踪多瑙河污染地点的上皮细菌生物膜群落的形态结构和分类学组成的季节性演替,高通量16SrRNA基因扩增子测序和多重/分类单元特异性PCR。生物膜样本是从同一淹没的石头中收集的,每两个月在多瑙河沿岸地区进行一次,在大城市的下游。扫描电镜显示生物膜由硅藻和多种形态不同的细菌组成。基于扩增子测序,细菌群落以假单胞菌和拟杆菌为主,而最丰富的古细菌属于门Nitrosossphaerota和纳米古细菌。环境因素的变化对表石微生物群落的组成有影响。水中粪便污染的临界水平与Sphaerotilus的相对丰度增加有关,“污水真菌”的典型指标,但是上皮性生物膜的组成和多样性也受到其他几个环境因素的影响,例如温度,水排放和总悬浮固体(TSS)。特定的PCR显示机会致病菌(例如假单胞菌属。,军团菌属。,铜绿假单胞菌,L.肺炎,嗜麦芽窄食单胞菌)在一些生物膜样品中,但是无法检测到超广谱β-内酰胺酶(ESBL)基因和大环内酯抗性基因。
    Epilithic biofilms are ubiquitous in large river environments and are crucial for biogeochemical processes, but their community structures and functions remain poorly understood. In this paper, the seasonal succession in the morphological structure and the taxonomic composition of an epilithic bacterial biofilm community at a polluted site of the Danube River were followed using electron microscopy, high-throughput 16S rRNA gene amplicon sequencing and multiplex/taxon-specific PCRs. The biofilm samples were collected from the same submerged stone and carried out bimonthly in the littoral zone of the Danube River, downstream of a large urban area. Scanning electron microscopy showed that the biofilm was composed of diatoms and a variety of bacteria with different morphologies. Based on amplicon sequencing, the bacterial communities were dominated by the phyla Pseudomonadota and Bacteroidota, while the most abundant archaea belonged to the phyla Nitrososphaerota and Nanoarchaeota. The changing environmental factors had an effect on the composition of the epilithic microbial community. Critical levels of faecal pollution in the water were associated with increased relative abundance of Sphaerotilus, a typical indicator of \"sewage fungus\", but the composition and diversity of the epilithic biofilms were also influenced by several other environmental factors such as temperature, water discharge and total suspended solids (TSS). The specific PCRs showed opportunistic pathogenic bacteria (e.g. Pseudomonas spp., Legionella spp., P. aeruginosa, L. pneumophila, Stenotrophomonas maltophilia) in some biofilm samples, but extended spectrum β-lactamase (ESBL) genes and macrolide resistance genes could not be detected.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景尽管慢性粒细胞白血病(CML)遗传学有进展,一氧化氮(NO)和硫化氢(H2S)基因突变的作用及其与凋亡基因的关系尚不清楚。因此,这项研究使用Sanger测序和下一代测序(NGS)调查了NO和H2S产生基因突变及其与凋亡基因的相互作用。方法进行全血细胞计数(CBC)以测量白细胞的总数,而IL-6水平在对照和CML患者中使用ELISA技术进行评估。Sanger测序用于分析CTH和NOS3基因的突变,而NGS用于检查所有染色体上的突变。结果CML患者的白细胞(WBC)和粒细胞计数明显高于对照组(p<0.0001),和单核细胞计数类似地更高(p<0.05)。白细胞介素-6(IL-6)水平在CML患者中显著高于对照组(p<0.0001),表明可能与CML病因或进展有关。已经在这两个基因中发现了多个突变,特别是在CTH外显子12和NOS3基因VNTR中,T786C,和G894T。本研究还使用IL-6测定法测量IL-6浓度,确定其作为CML预后诊断的潜力。白细胞计数,粒细胞计数,和中档绝对计数,或MID计数,CML患者明显高于正常对照组。NGS在CML患者中鉴定出1643个体细胞和性染色体异常和439个活跃表达的基因。与其他数据库相比,该发现暗示了CML发展中BCR-ABL1突变之外的基因组景观。结论总之,本研究通过鉴定NO-和H2S产生基因的突变及其与凋亡相关基因的复杂联系,促进了对CML遗传特征的理解.通过Sanger测序和NGS获得的全面遗传图谱为确定CML的治疗和个性化治疗的新目标提供了可能性。因此有助于血液病的发展。
    Background Despite advances in chronic myeloid leukemia (CML) genetics, the role of nitric oxide (NO) and hydrogen sulfide (H2S) gene mutations and their relationship to apoptotic genes is unclear. Therefore, this study investigated NO- and H2S-producing genes\' mutations and their interactions with apoptotic genes using Sanger sequencing and next-generation sequencing (NGS). Methodology A complete blood count (CBC) was carried out to measure the total number of white blood cells, while IL-6 levels were assessed in both control and CML patients using an ELISA technique. Sanger sequencing was used to analyze mutations in the CTH and NOS3 genes, whereas NGS was applied to examine mutations on all chromosomes. Results White blood cell (WBC) and granulocyte counts were significantly higher in CML patients compared to controls (p<0.0001), and monocyte counts were similarly higher (p<0.05). Interleukin-6 (IL-6) levels were significantly elevated in CML patients than controls (p<0.0001), indicating a possible link to CML etiology or progression. Multiple mutations have been identified in both genes, notably in CTH exon 12 and the NOS3 genes VNTR, T786C, and G894T. This study also measured IL-6 concentrations using IL-6 assays, identifying its potential as a CML prognostic diagnostic. WBC counts, granulocyte counts, and mid-range absolute counts, or MID counts, were significantly higher in CML patients than in normal control individuals. NGS identified 1643 somatic and sex chromosomal abnormalities and 439 actively expressed genes in CML patients. The findings imply a genomic landscape beyond the BCR-ABL1 mutation in CML development compared to other databases. Conclusion In conclusion, this study advances the understanding of the genetic characteristics of CML by identifying mutations in the NO- and H2S-producing genes and their complex connections with genes involved in apoptosis. The comprehensive genetic profile obtained by Sanger sequencing and NGS provides possibilities for identifying novel targets for therapy and personalized treatments for CML, therefore contributing to developments in hematological diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    甲型肝炎病毒(HAV),肝病毒属(PicornaviridaeHepV)的成员,仍然是一种重要的病毒病原体,经常在全球范围内引起经肠传播的肝炎。在这项研究中,我们对云南省野生小型陆生哺乳动物携带的HepV进行了流行病学调查,中国。利用HepV特异性广谱RT-PCR,下一代测序(NGS),和QNome纳米孔测序(QNS)技术,我们鉴定并表征了两种暂时命名为EpMa-HAV和EpLe-HAV的新型HepV,发现于长尾山sh(Episoriculusmacrurus)和长尾棕齿sh(Episoriculusleucops)中,分别。我们对EpMa-HAV和EpLe-HAV的序列和系统发育分析表明它们属于I型肝病毒(HepV-I)进化枝II,也被称为中国泼妇HepV进化枝。值得注意的是,新型HepV的密码子使用偏倚模式与先前鉴定的中国HepV一致。此外,我们的结构分析表明,与其他哺乳动物HepVs的RNA二级结构不同,并且在关键蛋白位点表现出差异.总的来说,在the中发现了两个新的HepV,扩大了HepV的宿主范围,并强调了HepV属中人类HAV的遗传多样性动物同源物的存在。
    Hepatitis A virus (HAV), a member of the genus Hepatovirus (Picornaviridae HepV), remains a significant viral pathogen, frequently causing enterically transmitted hepatitis worldwide. In this study, we conducted an epidemiological survey of HepVs carried by small terrestrial mammals in the wild in Yunnan Province, China. Utilizing HepV-specific broad-spectrum RT-PCR, next-generation sequencing (NGS), and QNome nanopore sequencing (QNS) techniques, we identified and characterized two novel HepVs provisionally named EpMa-HAV and EpLe-HAV, discovered in the long-tailed mountain shrew (Episoriculus macrurus) and long-tailed brown-toothed shrew (Episoriculus leucops), respectively. Our sequence and phylogenetic analyses of EpMa-HAV and EpLe-HAV indicated that they belong to the species Hepatovirus I (HepV-I) clade II, also known as the Chinese shrew HepV clade. Notably, the codon usage bias pattern of novel shrew HepVs is consistent with that of previously identified Chinese shrew HepV. Furthermore, our structural analysis demonstrated that shrew HepVs differ from other mammalian HepVs in RNA secondary structure and exhibit variances in key protein sites. Overall, the discovery of two novel HepVs in shrews expands the host range of HepV and underscores the existence of genetically diverse animal homologs of human HAV within the genus HepV.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    建立模块结合剂作为诊断检测剂代表了一次产生一个分子的常用结合剂的成本和时间有效的替代方案。与这些传统方法相比,模块化粘合剂可以从单个模块设计到,原则上,识别任何所需的线性表位,而无需经过选择和命中验证过程,给定一组预先存在的,氨基酸特异性模块。设计的Armadillo重复蛋白(dArmRP)已被开发为模块化粘合剂支架,我们在这里报告通过酵母表面显示选择生成高度特异性的dArmRP模块,在合理设计的dArmRP库上执行。开发了一种选择策略来区分由靶肽中的单个氨基酸突变产生的结合差异。在此引入的我们的反向竞争策略采用指定的靶标作为竞争物,以增加当从对靶标肽显示相似亲和力的交叉反应性结合物中分离特异性时的灵敏度。随着选择焦点从亲和力到特异性的转变,我们发现在这种特异性排序过程中的富集表明了所需的表型,无论粘合剂的丰度。因此,选择池的深度测序允许仅从下一代测序数据中检索选择性分选池中只有0.1%丰度的表型命中.在一项原理证明研究中,通过用新选择的模块替换所有相应的野生型模块来创建活页夹,产生对指定靶标具有非常高亲和力的结合剂,该结合剂已在蛋白质印迹分析中成功验证为检测剂。
    Establishing modular binders as diagnostic detection agents represents a cost- and time-efficient alternative to the commonly used binders that are generated one molecule at a time. In contrast to these conventional approaches, a modular binder can be designed in silico from individual modules to, in principle, recognize any desired linear epitope without going through a selection and hit-validation process, given a set of preexisting, amino acid-specific modules. Designed armadillo repeat proteins (dArmRP) have been developed as modular binder scaffolds, and we report here the generation of highly specific dArmRP modules by yeast surface display selection, performed on a rationally designed dArmRP library. A selection strategy was developed to distinguish the binding difference resulting from a single amino acid mutation in the target peptide. Our reverse-competitor strategy introduced here employs the designated target as a competitor to increase the sensitivity when separating specific from cross-reactive binders that show similar affinities for the target peptide. With this switch in selection focus from affinity to specificity, we found that the enrichment during this specificity sort is indicative of the desired phenotype, regardless of the binder abundance. Hence, deep sequencing of the selection pools allows retrieval of phenotypic hits with only 0.1% abundance in the selectivity sort pool from the next-generation sequencing data alone. In a proof-of-principle study, a binder was created by replacing all corresponding wild-type modules with a newly selected module, yielding a binder with very high affinity for the designated target that has been successfully validated as a detection agent in western blot analysis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在算法之间进行选择以及评估算法的HLA分型预测时,了解HLA分型算法的预期准确性很重要。本章指导读者通过一个示例基准测试研究,该研究评估了四个基于NGS的HLA分型算法的性能以及需要考虑的概述因素,在设计和运行这样的基准研究时。可以在https://github.com/nikolasthuesen/springers-hla-benchmark/上找到与此基准测试工作流程相关的代码。
    Knowledge of the expected accuracy of HLA typing algorithms is important when choosing between algorithms and when evaluating the HLA typing predictions of an algorithm. This chapter guides the reader through an example benchmarking study that evaluates the performances of four NGS-based HLA typing algorithms as well as outlining factors to consider, when designing and running such a benchmarking study. The code related to this benchmarking workflow can be found at https://github.com/nikolasthuesen/springers-hla-benchmark/ .
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    皮肤鳞状细胞癌是一种常见的恶性肿瘤,发病率上升,突变负荷显著高。探索cSCC的遗传细微差别和研究分子方法是改善高危患者预后的潜在途径。这项回顾性病例对照研究涉及两个队列,14名患者中的一名(“发现队列”)和12名患者中的另一名(“验证队列”),cSCC位于头/颈部解剖区域,并在pT2阶段诊断。总的来说,病例出现早期局部复发,而对照组在整个随访期间从未复发。对组织学样品进行的下一代测序(NGS)方法显示,TP53和CDKN2A是我们系列中最常见的突变基因。没有特异性突变被鉴定为潜在的预后或治疗靶标。与病例相比,对照显示出更高的突变率趋势。突变数量的增加可能会促使cSCC暴露更多的抗原,变得更具免疫原性并促进免疫系统的识别。这可以增强和维持免疫反应,可能会阻止未来的复发。
    Cutaneous squamous cell carcinoma is a prevalent malignancy with a rising incidence and a notably high mutational load. Exploring the genetic nuances of cSCC and investigating molecular approaches stands as a potential avenue for improving outcomes in high-risk patients. This retrospective case-control study involved two cohorts, one of 14 patients (the \"discovery cohort\") and the other of 12 patients (the \"validation cohort\"), with cSCC located in the head/neck anatomical region and diagnosed at the pT2 stage. Overall, cases developed early local relapses of the disease, whereas controls never relapsed during the entire follow-up period. A next-generation sequencing (NGS) approach conducted on histological samples revealed that TP53 and CDKN2A were the most frequently mutated genes in our series. No specific mutations were identified as potential prognostic or therapeutic targets. Controls exhibited a tendency toward a higher mutational rate compared to cases. It is possible that an increased number of mutations could prompt the cSCC to expose more antigens, becoming more immunogenic and facilitating recognition by the immune system. This could enhance and sustain the immunological response, potentially preventing future recurrences.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    “Pecorino”是一种典型的半硬奶酪,使用原料或热处理的羊奶,使用程序来提高原料的化学和微生物学特性。在本研究中,使用16SrRNA基因测序的高通量方法,我们使用来自Comisana和Lacaune绵羊品种的牛奶,在手工过程中评估了从牛奶到Pecorino样奶酪的微生物组组成的演变。对细菌群落组成的比较分析表明,在Comisana和Lacaune品种的牛奶微生物群中特定分类群的存在和丰度存在显着差异。下一代测序(NGS)分析还揭示了与奶牛养殖实践相关的凝乳微生物群的差异,对Pecorino奶酪微生物组的最终结构有相关影响。
    \"Pecorino\" is a typical semi-hard cheese obtained with raw or heat-treated sheep milk using procedures to valorize the raw material\'s chemical and microbiological properties. In the present study, using a high-throughput method of 16S rRNA gene sequencing, we assessed the evolution of the microbiome composition from milk to Pecorino-like cheese in artisanal processes using milk from Comisana and Lacaune sheep breeds. The comparative analysis of the bacterial community composition revealed significant differences in the presence and abundance of specific taxa in the milk microbiomes of the Comisana and Lacaune breeds. Next-Generation Sequencing (NGS) analysis also revealed differences in the curd microbiomes related to dairy farming practices, which have a relevant effect on the final structure of the Pecorino cheese microbiome.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号